Literature DB >> 32856034

Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States.

Michael W Fried1, Julie M Crawford1, Andrea R Mospan1, Stephanie E Watkins1, Breda Munoz1, Richard C Zink1, Sherry Elliott2, Kyle Burleson1, Charles Landis3, K Rajender Reddy4, Robert S Brown5.   

Abstract

BACKGROUND: As coronavirus disease 2019 (COVID-19) disseminates throughout the United States, a better understanding of the patient characteristics associated with hospitalization, morbidity, and mortality in diverse geographic regions is essential.
METHODS: Hospital chargemaster data on adult patients with COVID-19 admitted to 245 hospitals across 38 states between 15 February and 20 April 2020 were assessed. The clinical course from admission, through hospitalization, and to discharge or death was analyzed.
RESULTS: A total of 11 721 patients were included (majority were >60 years of age [59.9%] and male [53.4%]). Comorbidities included hypertension (46.7%), diabetes (27.8%), cardiovascular disease (18.6%), obesity (16.1%), and chronic kidney disease (12.2%). Mechanical ventilation was required by 1967 patients (16.8%). Mortality among hospitalized patients was 21.4% and increased to 70.5% among those on mechanical ventilation. Male sex, older age, obesity, geographic region, and the presence of chronic kidney disease or a preexisting cardiovascular disease were associated with increased odds of mechanical ventilation. All aforementioned risk factors, with the exception of obesity, were associated with increased odds of death (all P values < .001). Many patients received investigational medications for treatment of COVID-19, including 48 patients on remdesivir and 4232 on hydroxychloroquine.
CONCLUSIONS: This large observational cohort describes the clinical course and identifies factors associated with the outcomes of hospitalized patients with COVID-19 across the United States. These data can inform strategies to prioritize prevention and treatment for this disease.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; hydroxychloroquine; observational study; remdesivir

Mesh:

Substances:

Year:  2021        PMID: 32856034      PMCID: PMC7499515          DOI: 10.1093/cid/ciaa1268

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.

Authors:  Pablo Guisado-Vasco; Daniel Carnevali-Ruiz; Israel John Thuissard Vasallo
Journal:  EClinicalMedicine       Date:  2020-12-24

2.  Natural language processing enabling COVID-19 predictive analytics to support data-driven patient advising and pooled testing.

Authors:  Stéphane M Meystre; Paul M Heider; Youngjun Kim; Matthew Davis; Jihad Obeid; James Madory; Alexander V Alekseyenko
Journal:  J Am Med Inform Assoc       Date:  2021-12-28       Impact factor: 7.942

3.  Association of Patient Characteristics, Diabetes, BMI, and Obesity With Severe COVID-19 in Metropolitan Detroit, MI.

Authors:  Jaspreet Hehar; Erika Todter; Sharon W Lahiri
Journal:  Clin Diabetes       Date:  2022-04-15

Review 4.  Evidence-Based Considerations for the Design of an Open-Source Ventilator: A Systematic Review.

Authors:  Chintan Dave; Asaanth Sivajohan; John Basmaji; Marat Slessarev
Journal:  Crit Care Explor       Date:  2022-06-30

Review 5.  Inter-proteomic posttranslational modifications of the SARS-CoV-2 and the host proteins ‒ A new frontier.

Authors:  Suresh Mishra; Geetika Bassi; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-19

Review 6.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

7.  Clinical Characteristics and Risk Factors for Severe Outcomes of Novel Coronavirus Infection, January-March 2020, Japan.

Authors:  Yuuki Tsuchihashi; Yuzo Arima; Takuri Takahashi; Kazuhiko Kanou; Yusuke Kobayashi; Tomimasa Sunagawa; Motoi Suzuki
Journal:  J Epidemiol       Date:  2021-06-22       Impact factor: 3.211

8.  Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry.

Authors:  Juan Pablo Domecq; Amos Lal; Christopher R Sheldrick; Vishakha K Kumar; Karen Boman; Scott Bolesta; Vikas Bansal; Michael O Harhay; Michael A Garcia; Margit Kaufman; Valerie Danesh; Sreekanth Cheruku; Valerie M Banner-Goodspeed; Harry L Anderson; Patrick S Milligan; Joshua L Denson; Catherine A St Hill; Kenneth W Dodd; Greg S Martin; Ognjen Gajic; Allan J Walkey; Rahul Kashyap
Journal:  Crit Care Med       Date:  2021-03-01       Impact factor: 9.296

9.  Development of a multi-patient ventilator circuit with validation in an ARDS porcine model.

Authors:  Benjamin P Wankum; Riley E Reynolds; Andrea R McCain; Nathaniel T Zollinger; Keely L Buesing; Russel D Sindelar; Frank M Freihaut; Tariku Fekadu; Benjamin S Terry
Journal:  J Anesth       Date:  2021-06-01       Impact factor: 2.078

10.  Early Intubation and Increased Coronavirus Disease 2019 Mortality: A Propensity Score-Matched Retrospective Cohort Study.

Authors:  Austin J Parish; Jason R West; Nicholas D Caputo; Trevor M Janus; Denley Yuan; John Zhang; Daniel J Singer
Journal:  Crit Care Explor       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.